Bayer and burning rock collaborate to increase patient access to precision cancer medicines

Guangzhou, china, may 30, 2024 (globe newswire) -- burning rock biotech limited (nasdaq: bnr and lse: bnr, the “company” or “burning rock”) has recently announced a collaboration with bayer to develop next-generation sequencing (ngs)-based companion diagnostic assays (cdx), aiming to provide diagnostic methods, to enable treatment choice for patients with cancer in china, while driving innovation and development in cancer therapy. this collaboration will focus on the development of companion diagnostic products in china, jointly developing ngs-based cdx for bayer's growing portfolio of precision cancer therapies.
BNR Ratings Summary
BNR Quant Ranking